Ayushman Bharat Diwas: All you need to know about PM-Jan Arogya Yojana

-

The nation observes 30 April as Ayushman Bharat Diwas.  The day marks the launch of the Ayushman Bharat Yojana in 2018 by Prime Minister Narendra Modi. The scheme provides healthcare benefits to millions of Indians who cannot afford proper medical facilities.

The Ayushman Bharat scheme provides approximately 50 crore beneficiaries with coverage of up to Rs 5 lakh per family per year for secondary and tertiary care hospitalization. The main part of the healthcare scheme is the Pradhan Mantri-Jan Arogya Yojana (PM-JAY), which was launched in 2018.

On Ayushman Bharat Diwas, here is all you need to know about PM-JAY :

  • The PM- Jan Arogya Yojana is the largest health assurance scheme globally and covers over 10 crore poor and vulnerable families. These families form the bottom 40 percent of the country’s population.
  • The scheme provides a health cover of Rs 5 lakh per member every year for secondary and tertiary hospitalisation. All pre-existing conditions are covered from day under the scheme. COVID-19 is also covered under the PM-JAY scheme.
  • The scheme provides cashless hospitalization. It also covers 15 days of post-hospitalization expenses and up to three days of pre-hospitalization treatment costs.
  • The PM-JAY scheme is fully funded by the Union government. The cost of implementation is shared between the Centre and the states.
  • The PM-JAY is portable across the country, meaning that the beneficiaries can access cashless benefits from empanelled public/private healthcare facilities all over India.
  • Till date, over 3.11 crore hospital admissions have taken place under the scheme, according to the official website.
  • The government also launched the Ayushman Bharat CAPF scheme last year to provide cashless healthcare benefits to CAPF personnel from all seven forces- BSF, CISF, CRPF, Assam Rifles, ITBP, NSG and SSB. This personnel, and their dependents, will be provided the benefits through Ayushman Bharat PM-JAY IT platform.


from Firstpost India Latest News https://ift.tt/beE75nw
FP Trending

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more